Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Revision of Precautions

Romosozumab (genetical recombination)

September 6, 2019

Therapeutic category

Hormones-miscellaneous

Non-proprietary name

Romosozumab (genetical recombination)

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
(N/A)	Warnings The incidence of cardiovascular events (ischaemic heart disease or cerebrovascular disorder) tended to be higher in the romosozumab group than in the alendronate sodium group in a comparative study with alendronate sodium conducted overseas. In the post-marketing experience, cases of serious cardiovascular events have been reported, some of which resulted in death, although the causality between the drug and events is unknown. Proper patient selection should be required before this drug is administered based on adequate understanding of the benefit of reducing the risk of fracture and the onset risk of cardiovascular events. Patients should be closely monitored for the onset of cardiovascular events during treatment with this drug and instructed to seek medical attention immediately if any relevant signs or symptoms are observed.
Precautions concerning Indications This drug should be used in patients with risk factors of fracture, such as low bone density, past fracture, aging, a family history of femoral neck fracture, and so on.	Precautions concerning Indications This drug should be used in patients at a higher risk of fracture, in reference to descriptions as follows and others regarding severity in the diagnosis criteria of the Japanese Society for Bone and Mineral Research/Japan Osteoporosis Society. • Bone density level is -2.5 SD or lower with at least 1 fragility

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

The incidence of cardiovascular events (ischaemic heart disease or cerebrovascular disorder) tended to be higher in the romosozumab group than in the alendronate sodium group in a comparative study with alendronate sodium conducted overseas. Proper patient selection should be required before this drug is administered based on adequate understanding of its benefit and risk.	fracture. • Lumbar spinal bone density is less than -3.3 SD. • Two or more past vertebral fractures • Semiquantitative assessment score for past vertebral fracture is Grade 3. Proper patient selection should be required before this drug is administered based on adequate understanding of its benefit and risk.
Important Precautions Administration of this drug to patients at a higher risk of ischaemic heart disease or cerebrovascular disorder should be determined weighing the benefit and risk associated. Patients should be informed of the signs and symptoms of ischaemic heart disease or cerebrovascular disorder before the administration and instructed to seek medical attention immediately when the signs and symptoms appear. (N/A)	Important Precautions Patients should be informed of the signs and symptoms of ischaemic heart disease or cerebrovascular disorder associated before this drug is administered and instructed to seek medical attention immediately when the signs and symptoms appear. Administration to patients at a higher risk of ischaemic heart disease or cerebrovascular disorder should be determined weighing the benefit of reducing the risk of fracture and the onset risk of cardiovascular events. At least, administration of this drug

	should not be initiated to patients with a history of ischaemic heart disease or cerebrovascular disorder within the past year.

N/A: Not Applicable, because the section is not included in the current package insert.